Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Urogen Pharma Ltd (URGN)

21.37   0.9 (4.4%) 10-24 13:45
Open: 20.67 Pre. Close: 20.47
High: 21.52 Low: 20.4
Volume: 52,795 Market Cap: 471M
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. The company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 21.54 - 21.623 21.623 - 21.718
Low: 20.181 - 20.267 20.267 - 20.367
Close: 21.203 - 21.347 21.347 - 21.513

Technical analysis

as of: 2020-10-23 4:50:00 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 27.38     One year: 31.98
Support: Support1: 20.30    Support2: 18.36
Resistance: Resistance1: 23.44    Resistance2: 27.38
Pivot: 21.72
Moving Average: MA(5): 21.30     MA(20): 21.11
MA(100): 23.31     MA(250): 25.32
MACD: MACD(12,26): 0.07     Signal(9): 0.12
Stochastic oscillator: %K(14,3): 34.60     %D(3): 43.21
RSI: RSI(14): 49.82
52-week: High: 35.21  Low: 13.12  Change(%): -5.3
Average Vol(K): 3-Month: 15560  10-Days: 8079

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
URGN has closed above bottom band by 41.1%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 08 Oct 2020
Urogen Pharma (NASDAQ:URGN) Upgraded by BidaskClub to Hold - MarketBeat

Mon, 05 Oct 2020
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sat, 03 Oct 2020
$3.21 Million in Sales Expected for Urogen Pharma Ltd (NASDAQ:URGN) This Quarter - MarketBeat

Thu, 01 Oct 2020
UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic? - Simply Wall St

Mon, 10 Aug 2020
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments - Business Wire

Mon, 10 Aug 2020
UroGen Pharma Ltd. (URGN) Q2 2020 Earnings Call Transcript - Motley Fool

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 22
Shares Float (M) 19
% Held by Insiders 12.42
% Held by Institutions 81.28
Shares Short (K) 3,200
Shares Short P. Month (K) 3,130

Stock Financials

EPS -6.150
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 6.480
Profit Margin
Operating Margin -34154.03
Return on Assets (ttm) -39.7
Return on Equity (ttm) -71.0
Qtrly Rev. Growth 1966.7
Gross Profit (p.s.) 0.001
Sales Per Share 0.017
EBITDA (p.s.) -5.754
Qtrly Earnings Growth
Operating Cash Flow (M) -98
Levered Free Cash Flow (M) -47

Stock Valuations

PE Ratio -3.47
PEG Ratio
Price to Book value 3.30
Price to Sales 1264.97
Price to Cash Flow -4.80

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.